SequelSEC

Genprex, Inc. GNPX

Pharmaceutical Preparations · CIK 0001595248 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2024-12-31
Operating income
-$21.17M
Fiscal year ended 2024-12-31
Free cash flow
Unavailable
Fiscal year ended 2024-12-31

Genprex, Inc. (GNPX) reported revenue of $0 and net income of -$21.11M for the fiscal year ended 2024-12-31. This page shows 8 annual periods of income statement, balance sheet and cash flow figures normalized from Genprex, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Genprex, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-312018-12-312017-12-312016-12-31
Revenue$0$0$0$0$0$0$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$21.17M-$31.06M-$23.83M-$20.67M-$17.96M-$12.36M-$3.31M-$4.13M
Net income-$21.11M-$30.86M-$23.74M-$20.66M-$17.94M-$12.37M-$3.31M-$4.13M
Research & development$10.54M$17.62M$11.51M$8.97M$7.30M$971.43K$289.93K$354.88K
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$2.65K$0$0UnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPSUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$10.63M$13.43M$12.30M$11.68M$10.64M$11.39M$3.02M$3.78M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Genprex, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-312018-12-312017-12-312016-12-31
Cash & equivalents$1.60M$6.74M$20.95M$38.63M$27.32MUnavailable$161.25K$1.60M
Total assets$4.12M$10.67M$25.09M$42.86M$31.37M$9.27M$1.26M$1.91M
Current assets$2.08M$7.53M$21.47M$39.14M$27.70M$8.85M$193.57K$1.64M
Total liabilities$2.50MUnavailableUnavailable$1.59MUnavailableUnavailableUnavailableUnavailable
Current liabilities$2.50M$3.25M$2.81M$1.59M$450.72K$387.82K$830.96K$285.66K
Total equity incl. NCI$1.62M$7.42M$22.27M$41.28M$30.92M$8.88M$428.57K$1.62M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailable$0$34.85K$0$127$9.30K$8.84K$8.18K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

Genprex, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-312018-12-312017-12-312016-12-31
Operating cash flow-$17.92M-$24.74M-$17.62M-$14.28M-$13.94M-$6.85M-$2.17M-$1.25M
Capital expendituresUnavailableUnavailable$0$31.70K$17.56K$22.44K$5.89K$4.98K
Investing cash flow$774.64K-$71.21K-$59.74K-$83.80K-$2.34M-$103.32K-$63.42K-$89.53K
Financing cash flow$12.01M$10.59M$6.43K$25.68M$41.59M$15.39M$793.97K$2.71M
Net change in cash-$5.14M-$14.22M-$17.67M$11.31M$25.32M$8.44M-$1.44M$1.37M
Stock-based compensation$3.30M$5.41M$4.73M$5.35M$4.25M$5.44M$1.32M$2.66M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Genprex, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-312018-12-312017-12-312016-12-31
Free cash flowUnavailableUnavailableUnavailable-$14.32M-$13.95M-$6.87M-$2.18M-$1.25M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio0.83x2.31x7.64x24.69x61.47x22.81x0.23x5.74x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open GNPX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.